Faster reporting, integrated expertise, and growing scientific capability. One year after launching its in-house pharmacokinetic data analysis service, Agilex Biolabs reflects on how an integrated bioanalysis and PK model is helping sponsors accelerate clinical development decisions.
Immunogenicity testing is due for a rethink, as modern drug development shifts from rigid frameworks to smarter, clinically driven strategies.
Oligonucleotide therapeutics are transforming modern medicine, but analysing them is anything but simple. This article breaks down the three core challenges of oligonucleotide bioanalysis and the regulatory-ready LC-MS strategies required to generate reliable, submission-quality data.
Agilex Biolabs expands with a new Flow Cytometry Laboratory at QIMR Berghofer, boosting speed and precision in clinical research.
Contracted by the South Australian Government, Agilex Biolabs is deploying world-class science to sa...
Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new....
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No...
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the ris...
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in c...
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agi...
By Kim Salvatore, Head of Client and Operational Services The bioanalytical and drug development...
Research shows that Biotechnology companies have been facing significant challenges – with continu...
"*" indicates required fields
